Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock finished Wednesday's session 2.31% lower at $38.05. A total volume of 1.79 million shares was traded, which was above their three months average volume of 1.01 million shares. The Company's shares have advanced 14.09% in the past month, 10.19% in the previous three months, and 17.80% since the start of this year. The stock is trading 13.92% above its 50-day moving average. Additionally, shares of Pacira Pharma, which develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have a Relative Strength Index (RSI) of 59.18.
On January 03rd, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $43 per share.
On January 06th, 2017, Pacira Pharma reported preliminary unaudited 2016 revenues. The Company reported total revenues for Q4 2016 were $72.9 million, compared to $69.3 million for Q4 2015. Pacira Pharma EXPAREL net product sales for Q4 2016 were $71.4 million compared to $67.2 million for Q4 2015. The Company's total revenues for FY16 were $276.4 million compared to $249.0 million for FY15. EXPAREL net product sales for FY16 were $265.8 million, compared to $239.9 million for FY15. Your complete research report on PCRX can be retrieved for free at:
On Wednesday, shares in Rockville, Maryland-based Supernus Pharmaceuticals Inc. recorded a trading volume of 737,007 shares, which was above their three months average volume of 600,180 shares. The stock ended the session 3.45% lower at $25.20. The Company's shares have advanced 9.57% in the last one month and 9.57% over the previous three months. The stock is trading 9.55% above its 50-day moving average and 20.08% above its 200-day moving average. Moreover, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 53.08.
On December 12th, 2016, Supernus Pharma announced that the US Court of Appeals for the Federal Circuit affirmed the New Jersey District Court's decision that Actavis infringed two Oxtellar XR® Orange Book patents (US Patent Nos. 7,722,898 and 7,910,131) and that all three Oxtellar XR Orange Book patents (US Patent Nos. 7,722,898, 7,910,131, and 8,617,600) are valid. SUPN free report is just a click away at:
Shares in Salt Lake City, Utah Lipocine Inc. closed the day 1.76% lower at $3.35, with a total trading volume of 138,587 shares. The stock is trading 6.30% below its 50-day moving average. Shares of the Company, which develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health, have an RSI of 39.98.
On January 09th, 2017, Lipocine announced receipt of additional guidance from the US FDA on the LPCN 1107 pivotal Phase-3 clinical study design. LPCN 1107, a novel oral hydroxyprogesterone caproate product candidate that has been granted orphan drug designation by the FDA, is in development for the proposed indication of reducing the risk of preterm birth ("PTB") in women with singleton pregnancy who have a history of singleton spontaneous PTB. Sign up for your complimentary research report on LPCN at:
At the close, Toronto, Canada-based IntelliPharmaCeutics International Inc.'s stock finished 2.92% lower at $2.66, with a total trading volume of 167,694 shares. The Company's shares are trading above their 200-day moving average by 23.58%. Shares of the Company, which engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada, have an RSI of 41.75.
On January 06th, 2017, Intellipharmaceutics announced that its US marketing partner, Par Pharmaceutical (Par), has launched the 25 and 35 mg strengths of its generic Focalin XR® capsules in the US. The US FDA has granted final approval to Par's abbreviated new drug application for its generic Focalin XR® capsules in the 5, 10, 15, 20, 25, 30, 35 and 40 mg strengths. Register for free on Stock-Callers.com and download the latest research report on IPCI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA